Yahoo Web Search

Search results

    • Q1 2024 Syros Pharmaceuticals Inc Earnings Call

      Thomson Reuters StreetEvents via Yahoo Finance· 23 minutes ago

      And as I mentioned before, pivotal data from our Phase 3 SELECT-MDS-1 trials expected by mid Q4. As we approach these readouts. I'm also really pleased by our progress in ...

    • Q1 2024 Ocugen Inc Earnings Call

      Thomson Reuters StreetEvents via Yahoo Finance· 25 minutes ago

      By using nuclear hormone receptors to restore homeostasis in the retina, modifier gene therapy has the potential to address multiple inherited retinal diseases as well as diseases -- larger ...